



King Saud University  
College of Medicine  
1<sup>st</sup> Year, 4<sup>th</sup> Block

# Drug Therapy for Heart Failure 5&6



CARDIOVASCULAR BLOCK

# Objectives :

- 1 Describe the different classes of drugs used for treatment of acute & chronic heart failure
- 2 Describe the mechanism of action , therapeutic uses , side effects & drug interactions of individual drugs used for the treatment of heart failure


## Remember That :

**HEART FAILURE (HF) :** Inability of the heart to maintain an adequate cardiac output to meet the metabolic demands of the body ( **low cardiac output HF** )

❖ **High cardiac output although it is high but it can't meet the metabolic demand also it is RARE.**

**HF causes:** disorder of coronary arteries (**common**) – hypertension – cardiomyopathy – arrhythmia – heart valve disorder.





# Pathophysiology of CHF

## Heart failure symptoms

Tachycardia

rapid fatigue

Peripheral edema

Cardiomegaly

pulmonary congestion

**Low C.O**

Especially in  
R and L HF

**Dyspnea**


**Factors affecting cardiac output and Heart Failure:**

**Cardiac contractility**


**Preload ( high in HF patients)**

**Afterload ( high in HF patients)**


**Heart rate.**



Normal heart




Hypertrophic heart



Dilated (congestive) heart

Connective tissue  
**NOT** muscles.

# Drugs used in the treatment of heart failure



\* These drugs increase the myocardial contractility, also these drugs have + inotropic action.  
- **Heart rate** is involved in the processes above.

## Cardiac glycosides (Digoxin, Digitoxin, Oubain)

<b>Source</b>	Digitalis lanata ( a plant)
<b>Chemical structure</b>	Sugar & steroid like
<b>Mechanism of actions</b>	Inhibits Na <sup>+</sup> / K <sup>+</sup> ATPase enzyme
<b>Pharmacological actions</b>	<p>1- Direct increase in force of contraction of the myocardium ( +ve inotropic effect ).</p> <p>2- Increase of heart excitability and automaticity ( a sign of digoxin toxicity)</p> <p>3- A- slowing of conduction and prolongation of atrial &amp; A.V. node refractory period → ( In ECG : prolongation of the PR interval )          B- shortening of ventricular refractory period → ( In ECG : reduced QT interval )</p> <p>EXTRACARDIAC EFFECTS:increases vagal activity on the heart :</p> <p>1- Decrease of atrial refractory period leading to conversion of atrial flutter to fibrillation.</p> <p>2- Slowing of A.V. conduction. 3- Bradycardia</p>
<b>Therapeutic uses</b>	<p>1- Congestive heart failure → right or left.</p> <p>2- Atrial arrhythmias → Atrial flutter - Atrial fibrillation - Supraventricular tachycardia</p>
<b>Digoxin Pharmacokinetic</b>	<p>1- Drug has narrow therapeutic index. 2- <b>Absorption: orally : 40-80% leading to variable bioavailability. - I.V. acts within 15 min-3hrs</b></p> <p>3- metabolized in liver to cardioactive metabolite 4- excreted mainly by kidney.</p>
<b>Cardiac Adverse effects.</b>	digitalis-induced arrhythmias can cause any type of arrhythmia especially: <b>extrasystoles, coupled beats _ ventricular tachycardia or fibrillation _ A.V.block, cardiac arrest.</b>
<b>Extra-cardiac adverse effects( Other organs)</b>	<p>GIT : are common and among the <b>earliest signs of toxicity</b> : (Anorexia ,nausea,vomiting, diarrhea)</p> <p>C.N.S. :Headache, visual disturbances, drowsiness ( in old age)</p>
<b>contraindications</b>	Toxic myocarditis ( <b>viral- bacteria</b> ) - Constrictive pericarditis – Cardioversion ( <b>pacemaker</b> )
<b>Drugs interactions</b>	Diuretics→ hypokalemia (arrhythmia) - Quinidine : ↑plasma level of digitalis <b>With diuretics we should stop the drug or shift to K-sparing diuretics.</b>

## The physiological mechanism of $\text{Na}^+/\text{K}^+$ ase enzyme

It activates:

1.  $\text{Na}^+/\text{K}^+$  pump.
2.  $\text{Na}^+/\text{Ca}^+$  exchange ( Na in and Ca out)

## Digoxin

1- it inhibits  $\text{Na}^+/\text{K}^+$ ase enzyme as a result:

$\text{Na}^+/\text{K}^+$  pump and  $\text{Na}^+/\text{Ca}^+$  exchange **will be inhibited, this will increase the Ca and increases the contraction.**

2- it facilitates the entry of Ca through Ca channels  $\rightarrow$   $\uparrow$  intracellular Ca.

3- it triggers the sarcoplasmic reticulum to release Ca then increases the intracellular Ca.

## Factors increase digitalis toxicity:

1. Small Lean body mass→( the store of digoxin is the skeletal muscles so if the body mass is small there will be no store for digoxin and the free level of digoxin in the plasma will increase )
2. Renal diseases→ ( the main excretion site of digoxin is kidney)
3. Hypothyroidism→ ( they already have decreased metabolic rate of some drugs including digoxin)
4. Hypokalemia- Hypomagnesemia→ They increases the action of digoxin, because that patients who take diuretics( diuretics decrease potassium) and also take digoxin they may develop digitalis toxicity so they must take K supplements
5. Hypercalemia→ They increases the action of digoxin

## Treatment OF Adverse effects:

- 1) Stop the drug.
- 2) If they take diuretics ( not certain type) they have to stop it
- 3) But if they take **k sparing diuretics** they don't have to stop it.

- **FAB fragments** : a very expensive antibodies that stop the mechanism of digoxin immediately ( by binding to digoxin)

- **Antiarrhythmics**





## Phosphodiesterase Inhibitors Adverse effects

1. Nausea ,vomiting
2. Arrhythmias (less than digitalis )
3. **Thrombocytopenia**
4. **Liver toxicity**
5. Milrinone less hepatotoxic and less bone marrow depression than amrinone.

## Reduction of preload

### 1. Diuretics

General Diuretics → give k supplements.

potassium sparing diuretics → **no need** for k supplements.

#### Action

- Reduce salt and water retention → ↓ventricular preload and venous pressure.
- Reduction of edema and its symptoms.
- Reduction of cardiac size → improve cardiac performance.

#### Drug

hydrochlorothiazide

### 2. Venodilator

#### Action

Dilate venous capacitance vessels and reduce venous pressure and preload.

#### Drug

**Nitroglycerine** → used for **short term IV treatment of severe heart failure** when the main symptom is **dyspnea** due to pulmonary congestion.

Afterload=systemic vascular resistance.

## Reduction of afterload

### Arteriolodilators

#### Action


Reduce peripheral vascular resistance.

#### Drug

**hydralazine** → selective arteriolodilators , used when the main symptome is **rapid fatigue** due to **low cardiac output**.

# Reduction of preload and afterload

## 1. Renin-angiotensin-aldosterone system.



# Reduction of preload and afterload

## 1. Renin-angiotensin-aldosterone system.

Drugs acting on the renin- angiotensin - aldosterone system		
<b>Drugs</b>	<b>1- Angiotensin-converting enzyme inhibitors (ACEI)</b>	<b>2- Angiotensin receptor blockers ( ARBs)</b>
<b>e.g.</b>	<b>captopril - enalapril - lisinopril</b>	<b>losartan - valsartan - irbesartan</b>
<b>Mechanism of action</b>	<b>Inhibit angiotensin II production leading to:</b> - vasodilatation. ( reduction of peripheral resistance ) - Fall in aldosterone production.	- block AT1 receptors. - decrease actions of angiotensin II.
<b>Uses of ACEIs &amp; ARBS in HF</b>	↓ Peripheral resistance ( <b>Afterload</b> ). ↓ Venous return ( <b>Preload</b> ) . ↓ sympathetic activity . ↓ remodeling → ↓mortality rate (improve survival rate).	

## 2. Direct acting vasodilators.

- e.g. : **Sodium nitropruside.**
- given **I.V. in acute or severe refractory heart failure**, acts immediately and effects lasts for 1-5 minutes.

## Uses of $\beta$ - adrenoceptor antagonists ( $\beta$ blockers) in HF

### Not all ( $\beta$ blockers), just 3 drugs


- **Cardioselective:** (  $\beta_1$  receptors). e.g. Bisoprolol, Metoprolol
- **Non cardioselective:** (  $\beta_1$  &  $\beta_2$  ) &  $\alpha_1$ -adrenoceptor blocking effect . e.g carvedilol .

### Mechanism of beneficial $\beta$ - blockers effects in HF:

- Reduce remodeling through inhibition of the mitogenic activity of catecholamines.
- Reduce oxidative stress ( carvedilol ).
- Decrease heart rate .
- Attenuate the adverse effects of catecholamines.
- Inhibit renin release .
- Reduce the mortality rate.

### Using $\beta$ -blockers in HF patients with comorbidities

- After MI.
- **Chronic obstructive pulmonary disease:** treat with **cardioselective**.
- **Diabetes mellitus :** Reduce morbidity & mortality rate in diabetic patients with HF They have favorable metabolic effects.
- **Peripheral vascular disease :** **Carvedilol** due to its  $\alpha_1$ - blockade effect improve tolerability in patients with symptomatic claudication .



**Comorbidity** is the presence of one or more additional disorders (or diseases) *with* a primary disease or disorder.

## Management of chronic and acute HF

Chronic	Acute
<p>Reduce work load of the heart.</p> <ul style="list-style-type: none"> <li>Limits patient activity.</li> <li>Reduce weight.</li> <li>Control hypertension.</li> </ul>	Volume replacement
Restrict sodium	Positive inotropic drugs (Phosphodiesterase inhibitors and Dobutamine )
ACEI or ARBs	Vasodilators (Na nitropruside)
Digitalis	Antiarrhythmic drugs
$\beta$ - blockers	Treatment of myocardial infarction
Direct vasodilators	-----
Orally ←	→ IV
Diuretics	

# MCQs

**1. Drugs that decrease preload only :**

- a. Venodilators
- b. Arteriolodilators
- c. Directly-acting vasodilators
- d. Cardiac glycosides

**2. the drug which has Direct acting vasodilators and use for acute or severe refractory heart failure is :**

- a. Sodium nitropruside
- b. Enalapril
- c. valsartan
- d. Cardiac glycosides

**3. The Drugs use for management of Short term treatment of heart failure :**

- a. Venodilators
- b. Bipyridines
- c. Directly-acting vasodilators
- d. Cardiac glycosides

6.c

5.a

4.d

3.b

2.a

1.a

**4. The Management of acute heart failure :**

- a. Digitalis
- b. Restrict sodium
- c. Reduce weight
- d. Antiarrhythmic drugs

**5. the heart failure patient come to the emergency department. the doctor is dignosis Him by hepatotoxicity . What is the most likely drug to cause those symptoms :**

- a. Amrinone
- b. Diuretics
- c. Directly-acting vasodilators
- d. Venodilators

**6. In ECG : the slowing of conduction and prolongation of atrial and A.V. node refractory period show as :**

- a. Decrease R-R interval
- b. reduced QT interval
- c. prolongation of the PR interval
- d. NO P WAVE





# THIS WORK WAS DONE BY :

Contact us for any questions or  
comments :



Pharma\_433@yahoo.com



@pharma\_433

Nada Dammas

Ahmed Aldakhil

Awatif Alenezi

Aisha Alraddadi

Yara Alenezi

**We hope that we made this lecture easier for you  
Good Luck !**